| Description |
1 online resource (vi, 288 pages) |
| Series |
Advances and Controversies in Hematopoietic Transplantation and Cell Therapy |
|
Advances and controversies in hematopoietic transplantation and cell therapy.
|
| Contents |
Intro; Contents; 1: Historical Perspective and Current Focus; 2: Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018; 2.1 Introduction; 2.2 Relapsed/Refractory B-Lineage Acute Lymphoblastic Leukemia; 2.2.1 Children and Young Adults: CAR T Cells Show Promising Results; 2.2.2 Children and Young Adults: Tisagenlecleucel (CTL019) and Its US FDA Approval (2017); 2.2.3 Adults with Relapsed/Refractory B-ALL: Phase I Trial from Memorial Sloan Kettering Cancer Center (MSKCC); 2.3 Non-Hodgkin B-Cell Lymphomas |
|
2.3.1 Phase I, ZUMA-1 Study (Locke et al. 2017a): Primary Results of Axicabtagene Ciloleucel (KTE-C19) with a Focus on Refractory Diffuse Large B-Cell Lymphoma (DLBCL)2.3.2 Additional Results of ZUMA-1 Study (Locke et al. 2017b) and US FDA Approval (2017) of Axicabtagene Ciloleucel (KTE-C19); 2.3.3 Phase II Results of ZUMA-1 Study (Neelapu et al. 2017): Axicabtagene Ciloleucel in DLBCL, PMBCL, and Transformed FL; 2.3.4 Tisagenlecleucel (CTL019) in Relapsed/Refractory DLBCL and Follicular Lymphoma: Results from University of Pennsylvania (UPenn) (Schuster et al. 2017a) |
|
2.3.5 US FDA Approval (2018) of Tisagenlecleucel (CTL019) for Adults with Relapsed/Refractory Large B-Cell Lymphoma: Results of JULIET Study (Schuster et al. 2017b, c)2.3.6 Long Duration of CR in DLBCL After Anti-CD19 CAR T-Cell Therapy: Data from the NCI (Kochenderfer et al. 2017); 2.4 Chronic Lymphocytic Leukemia; 2.4.1 CLL and Anti-CD19 CAR T Cells Following Ibrutinib Failure; 2.5 Multiple Myeloma; 2.5.1 Results of Anti-BCMA CAR T Cells: Data from NCI (Ali et al. 2016; Brudno et al. 2017); 2.5.2 Anti-BCMA CAR T Cells: Data Presented at ASH® 2017 by UPenn (Cohen et al. 2017) |
|
2.5.3 CRB-401: A Multicenter Trial Phase I Dose Escalation Trial of bb21212.5.4 Data from China with Unique Antigen-Binding Domain: Late Breaking Abstract at ASCO® 2017; 2.6 Classic Hodgkin and Anaplastic Large-Cell Lymphomas; 2.6.1 CD30-Directed CAR T Cell: Phase I Study in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma (cHL) and Anaplastic Large-Cell Lymphoma (ALCL); 2.6.2 CD30-Directed CAR T Cell: Another Phase I Study in Patients with Relapsed/Refractory cHL and ALCL; 2.7 Considerations for Tisagenlecleucel Dosing Rationale |
| Summary |
In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee |
| Notes |
Print version record |
| Subject |
Cellular therapy.
|
|
Gene therapy.
|
|
Cell- and Tissue-Based Therapy
|
|
Genetic Therapy
|
|
Cellular therapy
|
|
Gene therapy
|
| Form |
Electronic book
|
| Author |
Perales, Miguel-Angel, editor
|
|
Abutalib, Syed A., editor
|
|
Bollard, Catherine, editor
|
| ISBN |
9783319543680 |
|
3319543687 |
|
3319543679 |
|
9783319543673 |
|
